|
TGOLN2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.70909999988689E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.5546199999994E-05 |
| Normal-vs-Stage2 |
4.573800E-04 |
| Normal-vs-Stage3 |
5.1466000017264E-08 |
| Normal-vs-Stage4 |
1.64897999999081E-05 |
| Stage1-vs-Stage2 |
7.951800E-01 |
| Stage1-vs-Stage3 |
1.548850E-01 |
| Stage1-vs-Stage4 |
4.286600E-01 |
| Stage2-vs-Stage3 |
5.070600E-01 |
| Stage2-vs-Stage4 |
6.884000E-01 |
| Stage3-vs-Stage4 |
8.411600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.06860000004261E-06 |
| Normal-vs-AfricanAmerican |
1.260650E-01 |
| Normal-vs-Asian |
6.33650000025909E-07 |
| Caucasian-vs-AfricanAmerican |
8.914300E-02 |
| Caucasian-vs-Asian |
2.115600E-01 |
| AfricanAmerican-vs-Asian |
1.347710E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.0113999960335E-08 |
| Normal-vs-Female |
3.07669999999316E-06 |
| Male-vs-Female |
9.282300E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.7774000000157E-06 |
| Normal-vs-Age(41-60Yrs) |
1.57411999999191E-05 |
| Normal-vs-Age(61-80Yrs) |
9.47410000007309E-07 |
| Normal-vs-Age(81-100Yrs) |
1.794360E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.567800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.813800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.461600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.536200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.404200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.511000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.741400E-03 |
| Classical-VS-Follicular |
1.595420E-01 |
| Classical-VS-Other |
1.047440E-01 |
| Classical-VS-Normal |
1.79847999999261E-05 |
| Tall-VS-Follicular |
3.200600E-01 |
| Tall-VS-Other |
6.478400E-01 |
| Tall-VS-Normal |
1.51880000021087E-07 |
| Follicular-VS-Other |
4.026000E-01 |
| Follicular-VS-Normal |
3.9522000000014E-05 |
| Other-VS-Normal |
2.157200E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.95629999999447E-06 |
| Normal-vs-N1 |
1.78879999701564E-08 |
| N0-vs-N1 |
3.910400E-02 |
|
|
